South & Central America Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type (Vitamin D and Calcium Supplement, Protein Supplement, Vitamin B12 Supplement, and Others) and Distribution Channel (Pharmacies, Retail Channels,

South & Central America Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type (Vitamin D and Calcium Supplement, Protein Supplement, Vitamin B12 Supplement, and Others) and Distribution Channel (Pharmacies, Retail Channels, Online Channels, and Others)

The South & Central America sarcopenia treatment market was valued at US$ 189.59 million in 2022 and is expected to reach US$ 268.50 million by 2030; it is estimated to register a CAGR of 4.4% from 2022 to 2030 .

Products in Clinical Trial Phases Fuel South & Central America Sarcopenia Treatment Market

A few major players operating in the sarcopenia treatment market are increasingly focusing on drug development to treat sarcopenia. Novel sarcopenia treatments are currently being developed and tested in clinical trials. A few of these products are mentioned below:

Sarcopenia Drug Under Clinical Development
Company Name
Interventions
Conditions
Clinical Trial Stage
Abbott Nutrition
Medical Food with AN777
Oral Nutritional Formula
Malnutrition
Sarcopenia
PHASE3
Nutricia Research
Dietary Supplement: Bolus ONS A
Dietary Supplement: Bolus ONS B
Dietary Supplement: Bolus ONS C
Dietary Supplement: Bolus ONS D
Sarcopenia
PHASE1
Novartis Pharmaceuticals
Drug: Bimagrumab
Sarcopenia
PHASE2
McMaster University
Behavioural: Step Reduction
Sarcopenia
PHASE1
Metabolic Technologies Inc.
Dietary Supplement: Placebo
Drug: HMB Plus Vitamin D
Behavioural: Non-Exercise
Behavioural: Exercise
Sarcopenia
PHASE1
Merck Sharp & Dohme LLC
Drug: Comparator MK-077
Drug: Comparator Placebo
Sarcopenia
PHASE2
Immunotec Inc.
Dietary Supplement: Immunocal
Dietary Supplement: Casein
Aging and Sarcopenia
PHASE2
Lijun Yang
Combination Product: 3-Month Intensive Intervention
Sarcopenia
PHASE4
Regeneron Pharmaceuticals
Drug: REGN1033 (SAR391786)
Drug: Placebo
Sarcopenia
PHASE2
Source: Company Websites and The Insight Partners Analysis

Therefore, the extending pipeline of drugs that are in different stages of clinical development presents significant opportunities for the sarcopenia treatment market growth.

South & Central America Sarcopenia Treatment Market Overview

The sarcopenia treatment market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. A rise in the geriatric population and the surging incidence of vitamin Deficiency fuels the sarcopenia treatment market in South & Central America.

The introduction of new regulations by the National Sanitary Surveillance Agency (ANVISA) for dietary supplements in 2018 made the entry of new brands easier in Brazil. Moreover, it helped existing brands to flourish and innovate in the country. According to a study published in the National Library of Medicine, the elderly population is rapidly growing in Brazil, resulting in an increased prevalence of chronic conditions associated with old age. The overall prevalence of sarcopenia in the elderly population in Brazil was ~20.0% in 2020. According to an article published by National Institute of Health, in 2022, the prevalence of probable sarcopenia is 42.0% in older Brazilian women.

South & Central America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Sarcopenia Treatment Market Segmentation

The South & Central America sarcopenia treatment market is categorized into treatment type, distribution channel, and country.

Based on treatment type, the South & Central America sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest South & Central America sarcopenia treatment market share in 2022.

In terms of distribution channel, the South & Central America sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest South & Central America sarcopenia treatment market share in 2022.

By country, the South & Central America sarcopenia treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America sarcopenia treatment market share in 2022.

Abbott Laboratories, Bayer AG, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc are some of the leading companies operating in the South & Central America sarcopenia treatment market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America sarcopenia treatment market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America sarcopenia treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America sarcopenia treatment market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.